Citigroup’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Citigroup’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-99,775	Closed	-$665K	–	5907
2023 Q3	$665K	Buy	99,775 +17,913	+22%	+$149K	﹤0.01%	2838
2023 Q2	$742K	Sell	81,862 -55,417	-40%	-$489K	﹤0.01%	3064
2023 Q1	$998K	Buy	137,279 +6,003	+5%	+$44.5K	﹤0.01%	2562
2022 Q4	$957K	Sell	131,276 -8,602	-6%	-$63.8K	﹤0.01%	2639
2022 Q3	$1.08M	Buy	139,878 +76,730	+122%	+$651K	﹤0.01%	2655
2022 Q2	$430K	Buy	63,148 +50,477	+398%	+$386K	﹤0.01%	3349
2022 Q1	$101K	Buy	12,671 +12,007	+1,808%	+$76.2K	﹤0.01%	4411
2021 Q4	$4K	Buy	+664	New	+$4.98K	﹤0.01%	5696

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Citigroup's PNT Position: Q4 2023 in Review

Citigroup sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 99,775 shares — an estimated $665K sold.

Citigroup first reported a position in PNT in Q4 2021 and held it in 8 quarters. The position peaked at $1.08M in Q3 2022. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Citigroup reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Citigroup sold 99,775 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $665K.
Citigroup first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Citigroup's POINT Biopharma Global Inc. Common Stock position peaked at $1.08M in Q3 2022.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Citigroup's 13F filing for Q4 2023, filed 9 Feb 2024.